Viagra Professional (Sildenafil)

Figure 1: Location diagrammatic muscle in the walls of intraacinar arteries. In newbornsnormal less than 1 week old, is not found in muscle acinar arteries. Allpatients with persistent pulmonary hypertension showed the extent of muscularization for smallarteries within the acinares. Murphy J, Rabinovitch M, Goldstein J, et al. The Structural Basis of persistentpulmonary hypertension of the newborn infant

AAccording to Walsh and Stork, efforts to treat infants with PPHN oftenlead to suboptimal results with substantial morbidity and mortality. The reason is that the HPPRN is not one disease but many diseases that several pathophysiologiespresent with similar clinical picture. Seen from this angle, it is clear that differenttherapeutic approaches are needed for different pathophysiologies. The current management of this condition includes therapies aimed at decreasing the resistancepulmonary vascular and between them stands out the use of inhaled nitric oxide (i NO) 6. The i NO produces specific pulmonary vasodilation by increasingconcentration of 5 cyclic guanosine monophosphate (c GMP) in the smooth muscle ofarteries and is useful in treating PPH of the newborn, primary pulmonary hypertension and hypertensionearly lung following cardiac surgery. Through the activation of protein kinaseby c GMP, an increase of the opening of calciumsensitive potassium channels, withhyperpolarization of the membrane with ibio in calcium influx through the channels Ltype calcium, causing relaxation of arterial smooth muscle. The c GMP is 6 subsequently inactivated by phosphodiesterase type 5 (PDE 5). The use of i NO has been a standard therapy, but 30% of cases failin response, thus do not constitute a single magic bullet for the treatment of PPH of the newborn. The vasodilation that occurs with i NO is transient, since i NO rapidly (<10 sec) degraded in the presence of O 2, losing its bioactivity. The extremely short halflifeensures that i NO has no systemic adverse effects. The nonresponse to i NO isdue to parenchymal disease, heart failure or problems in signaling No 7 c GMP. The PDE are enzymes that catalyze the hydrolytic cleavage of the link 3 fosfodiesterof cyclic nucleotides by controlling their intracellular levels. Among the 11 distinct PDE families, there is a predominance of PDE 5 in vascular smooth muscle cellslung, which is why there are several studies exploring the therapeutic potential of 7 PDE 5 inhibitors in pulmonary hypertension. 8 Study Hanson and classic animal model of fetal pulmonary hypertension hasevidenced increased activity of PDE 5 and that this increase contributes to reactivityperinatal pulmonary vascular hypertension. Thus, an alternative approach or assist in the management of PPH of the newborncan be increased endogenous concentration of c GMP using specific inhibitors PDE 5 (Figure 2).